Dow Down1.40% Nasdaq Down1.59%

Dynavax Technologies Corporation (DVAX)

-NasdaqCM
1.42 Down 0.01(0.70%) 4:00PM EDT
ProfileGet Profile for:
Dynavax Technologies Corporation
2929 Seventh Street
Suite 100
Berkeley, CA 94710
United States - Map
Phone: 510-848-5100
Website: http://www.dynavax.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:151

Business Summary 

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Dynavax Technologies Corporation

Corporate Governance 
Dynavax Technologies Corporation’s ISS Governance QuickScore as of Sep 1, 2014 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Eddie Gray , 54
Chief Exec. Officer and Director
783.00K0.00
Dr. Dennis A. Carson Ph.D., M.D., 67
Co-Founder and Director
40.00KN/A
Mr. Michael S. Ostrach J.D., 62
Principal Financial Officer, Chief Bus. Officer, Gen. Counsel, VP and Sec.
530.00K0.00
Mr. David F. Novack , 52
Sr. VP of Operations and Quality
462.00K0.00
Dr. Robert L. Coffman Ph.D., 67
Chief Scientific Officer and VP
457.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders